Poster Session E - Tuesday Afternoon
Joelle BouSaba, MD
Mayo Clinic
Rochester, MN

| All patients (n=93) | |
| Age, in years, mean (SD) | 30 (15) |
| Sex assigned at birth, Female, N(%) | 59 (63) |
| Sexual orientation, N(%) | |
| Bisexual | 48 (52) |
| Gay/lesbian/homosexual | 39 (42) |
| Other | 5 (5) |
| Prefer not to disclose | 1(1) |
| Gender Identity, N(%) | |
| Female | 52 (56) |
| Male | 30 (32) |
| Genderqueer | 2 (2) |
| Transgender female | 2 (2) |
| Other | 7 (8) |
| Race, N(%) | |
| White | 85 (92) |
| Black | 3 (3) |
| American indian/Alaska native | 1 (1) |
| Asian | 1 (1) |
| Native Hawaiian/Pacific Native Islander | 1 (1) |
| Other | 2 (2) |
| IBD diagnosis, N(%) | |
| Ulcerative colitis | 48 (52) |
| Crohn's Disease | 45 (48) |
| IBD medications at initial visit, (n=37) | |
| Mesalamine | 20 (54) |
| Corticosteroids | 15 (41) |
| Thiopurines | 10 (27) |
| Infliximab | 8 (21) |
| Adalimumab | 7 (19) |
| Vedolizumab | 2 (5) |
| Ustekinumab | 2 (5) |
| Certolizomab | 2 (5) |
| Methotrexate | 1 (3) |